Sarepta Therapeutics (SRPT) Tops Q3 EPS by 68c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of $0.62, $0.68 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $467.2 million versus the consensus estimate of $407.73 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• MGE Energy (MGEE) Declares $0.5083 Quarterly Dividend; 2.6% Yield
• Thunder Mountain Gold closes $5.7M private placement